Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ · Manufacturing · Pharmaceutical preparations
$91.30+$1.94 (+2.17%) on the dayAs of the close; data may be delayed.
MIRM price, last 12 months
Key stats
- Previous close
- $89.36
- Open
- $90.00
- Day range
- $88.28 – $92.00
- 52-week range
- $63.23 – $130.00
- Volume
- 610.5K
- Avg volume (20 days)
- 669.4K
- Market cap
- $5.8B
Performance
1W−0.6%
1M−7.3%
3M−26.2%
6M+2.7%
YTD+15.6%
1Y+23.0%
vs S&P 500, 1Y+6.2 pts
Technicals and fundamentals
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.8B